{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:44:59Z","timestamp":1794134699659,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.eururo.2008.11.002","type":"journal-article","created":{"date-parts":[[2008,11,30]],"date-time":"2008-11-30T09:16:55Z","timestamp":1228036615000},"page":"1112-1123","source":"Crossref","is-referenced-by-count":131,"title":["Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial"],"prefix":"10.1016","volume":"55","author":[{"given":"Nicholas D.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Caty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Zonnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.11.002_bib1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.11.002_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ucl.2005.12.010","article-title":"Mechanisms leading to the development of hormone-resistant prostate cancer","volume":"33","author":"Kasper","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2008.11.002_bib3","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.ju.0000095102.34708.bc","article-title":"Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer","volume":"170","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.11.002_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2006.08.013","article-title":"Current indications for chemotherapy in prostate cancer patients","volume":"51","author":"Calabr\u00f2","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.11.002_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","article-title":"EAU guidelines on prostate cancer","volume":"53","author":"Heidenreich","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.11.002_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.pcan.4500880","article-title":"The changing pattern of management for hormone-refractory, metastatic prostate cancer","volume":"9","author":"James","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2008.11.002_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1479-5876-2-16","article-title":"Endothelin receptors as novel targets in tumor therapy","volume":"2","author":"Bagnato","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.eururo.2008.11.002_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc990","article-title":"The endothelin axis: emerging role in cancer","volume":"3","author":"Nelson","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2008.11.002_bib9","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1074\/jbc.273.20.12584","article-title":"Endothelin-induced apoptosis of A375 human melanoma cells","volume":"273","author":"Okazawa","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eururo.2008.11.002_bib10","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1006\/bbrc.1994.1395","article-title":"Clearance of circulating endothelin-1 by ETB receptors in rats","volume":"199","author":"Fukuroda","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.eururo.2008.11.002_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(25)12297-0","article-title":"Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist","volume":"276","author":"Opgenorth","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.eururo.2008.11.002_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.11.002_bib13","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2008.11.002_bib14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1517\/13543784.17.8.1237","article-title":"ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer","volume":"17","author":"Warren","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl","key":"10.1016\/j.eururo.2008.11.002_bib15","first-page":"153","article-title":"The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment","volume":"6","author":"Curwen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2008.11.002_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1359-6349(06)70042-8","article-title":"The combination of a specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents bone metastasis","volume":"4","author":"Williams","year":"2006","journal-title":"Eur J Cancer Suppl"},{"issue":"Suppl","key":"10.1016\/j.eururo.2008.11.002_bib17","first-page":"247","article-title":"Phenotypic in vitro differentiation of the specific endothelin A receptor antagonist, ZD4054, from the selective endothelin antagonist, atrasentan","volume":"6","author":"Growcott","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2008.11.002_bib18","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.bjc.6602676","article-title":"Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence","volume":"92","author":"Morris","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2008.11.002_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2008.11.002_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.eururo.2008.11.002_bib21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2008.11.002_bib22","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.22995","article-title":"The hazards of intermediate endpoints","volume":"110","author":"Beer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2008.11.002_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.11.002_bib24","doi-asserted-by":"crossref","unstructured":"Small EJ, Schellhammer PF, Higano C, Neumanaitis J, Valone F, Herschberg RM. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final survival data from a phase 3 randomized placebo-controlled trial. In: Proceedings from the American Society of Clinical Oncology Prostate Cancer Symposium 2005. Abstract 264.","DOI":"10.1016\/S1359-6349(05)82004-X"},{"key":"10.1016\/j.eururo.2008.11.002_bib25","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.11.002_bib26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-06-1885","article-title":"The association between measures of progression and survival in castrate-metastatic prostate cancer","volume":"13","author":"Scher","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2008.11.002_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.CIR.0000110644.92116.91","article-title":"Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development","volume":"109","author":"Konstam","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2008.11.002_bib28","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2008.11.002_bib29","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2008.11.002_bib30","unstructured":"Slosman D, Keller A, Phung D, Freneaux E. Standardized protocol to monitor metastatic bone progression by bone scintigraphy in multicentre clinical trials. In: Proceedings from the First European Multidisciplinary Meeting on Urological Cancers; 2\u20134 November 2007; Barcelona, Spain. Abstract P86."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808013092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808013092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T01:33:26Z","timestamp":1738719206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808013092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0302283808013092"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.11.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}